Lucid Diagnostics Inc. LUCD
We take great care to ensure that the data presented and summarized in this overview for Lucid Diagnostics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LUCD
View all-
Masters Capital Management LLC Atlanta, GA2.73MShares$3.49 Million0.21% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.89MShares$2.42 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA889KShares$1.14 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny459KShares$587,6030.0% of portfolio
-
Luminus Management LLC Houston, TX457KShares$584,5040.62% of portfolio
-
Ghisallo Capital Management LLC Greenwich, CT422KShares$540,1650.24% of portfolio
-
Sunbelt Securities, Inc. Houston, TX384KShares$491,5180.06% of portfolio
-
Lido Advisors, LLC Los Angeles, CA383KShares$490,3440.0% of portfolio
-
Geode Capital Management, LLC Boston, MA303KShares$388,0640.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny204KShares$261,1800.0% of portfolio
Latest Institutional Activity in LUCD
Top Purchases
Top Sells
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Insider Transactions at LUCD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2025
|
Dennis Matheis Director |
BUY
Open market or private purchase
|
Direct |
33,218
+8.67%
|
$33,218
$1.32 P/Share
|
|
May 21
2025
|
Dennis Matheis Director |
BUY
Open market or private purchase
|
Direct |
129,684
+29.05%
|
$129,684
$1.32 P/Share
|
|
May 20
2025
|
Dennis Matheis Director |
BUY
Open market or private purchase
|
Direct |
187,098
+50.0%
|
$187,098
$1.29 P/Share
|
|
Feb 20
2025
|
Shaun O'Neil President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+26.62%
|
-
|
|
Feb 20
2025
|
Lishan Aklog Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+16.98%
|
-
|
|
Feb 20
2025
|
Jacque J Sokolov Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,800
+36.36%
|
-
|
|
Feb 20
2025
|
Stanley Lapidus Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,800
+34.48%
|
-
|
|
Feb 20
2025
|
Dennis Matheis Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,800
+40.94%
|
-
|
|
Feb 20
2025
|
James L Cox Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,800
+28.56%
|
-
|
|
Feb 20
2025
|
Dennis M Mcgrath Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+18.25%
|
-
|
|
Feb 20
2025
|
Michael Adam Gordon General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+30.0%
|
-
|
|
Feb 20
2025
|
Debra White Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,800
+50.0%
|
-
|
|
Feb 20
2025
|
Ronald M Sparks Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,800
+36.36%
|
-
|
|
May 07
2024
|
Lishan Aklog Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+25.53%
|
-
|
|
May 07
2024
|
Dennis M Mcgrath Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+27.71%
|
-
|
|
May 07
2024
|
Shaun O'Neil President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+43.16%
|
-
|
|
May 07
2024
|
Michael Adam Gordon General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+50.0%
|
-
|
|
Feb 15
2024
|
Pa Vmed Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
3,331,747
-9.62%
|
-
|
|
Jan 26
2024
|
Pa Vmed Inc. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
3,331,771
+8.78%
|
$3,331,771
$1.4 P/Share
|
|
Sep 26
2023
|
Stanley Lapidus Director |
SELL
Open market or private sale
|
Direct |
29,747
-8.2%
|
$29,747
$1.45 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.88M shares |
|---|---|
| Open market or private purchase | 350K shares |